Hainan Honz Pharmaceutical Co Total Assets
Hainan Honz Pharmaceutical Co total assets. Based on the latest financial reports, Hainan Honz Pharmaceutical Co (300086) holds total assets worth CN¥1.71 Billion CNY (≈ $250.47 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 300086 market cap for the company's overall valuation and market capitalisation.
Total Assets of Hainan Honz Pharmaceutical Co (2007–2025)
Total assets of Hainan Honz Pharmaceutical Co from 2007 to 2025. This chart illustrates how Hainan Honz Pharmaceutical Co's total assets have evolved over time, based on quarterly financial data. See 300086 live share price for real-time trading data and today's change.
Hainan Honz Pharmaceutical Co - Asset Composition Analysis
Hainan Honz Pharmaceutical Co Total Assets Breakdown (December 2025)
Hainan Honz Pharmaceutical Co total assets breakdown as of December 2025. Hainan Honz Pharmaceutical Co's total assets of CN¥1.71 Billion consist of 17.0% current assets and 83.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.3% |
| Accounts Receivable | CN¥36.77 Million | 2.1% |
| Inventory | CN¥160.12 Million | 8.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥94.79 Million | 5.3% |
| Goodwill | CN¥8.30 Million | 0.5% |
Asset Composition Trend (2007–2025)
This chart illustrates how Hainan Honz Pharmaceutical Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Hainan Honz Pharmaceutical Co short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hainan Honz Pharmaceutical Co's current assets represent 17.0% of total assets in 2025, a decrease from 67.8% in 2007.
- Cash Position: Cash and equivalents constituted 3.3% of total assets in 2025, down from 42.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 8.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 8.9% of total assets.
Hainan Honz Pharmaceutical Co Competitors by Total Assets
Key competitors of Hainan Honz Pharmaceutical Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Hainan Honz Pharmaceutical Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.46 | 0.74 | 1.61 |
| Quick Ratio | 0.16 | 0.37 | 1.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-308.85 Million | CN¥-116.10 Million | CN¥268.46 Million |
Hainan Honz Pharmaceutical Co - Advanced Valuation Insights
This section examines the relationship between Hainan Honz Pharmaceutical Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.52 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | -9.4% |
| Total Assets | CN¥1.79 Billion |
| Market Capitalization | $314.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hainan Honz Pharmaceutical Co's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hainan Honz Pharmaceutical Co's assets decreased by 9.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hainan Honz Pharmaceutical Co (2007–2025)
The table below shows the annual total assets of Hainan Honz Pharmaceutical Co from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.79 Billion ≈ $262.08 Million |
-9.36% |
| 2024-12-31 | CN¥1.98 Billion ≈ $289.13 Million |
-8.76% |
| 2023-12-31 | CN¥2.17 Billion ≈ $316.90 Million |
-5.37% |
| 2022-12-31 | CN¥2.29 Billion ≈ $334.88 Million |
-6.93% |
| 2021-12-31 | CN¥2.46 Billion ≈ $359.80 Million |
-5.93% |
| 2020-12-31 | CN¥2.61 Billion ≈ $382.46 Million |
+19.11% |
| 2019-12-31 | CN¥2.19 Billion ≈ $321.11 Million |
+0.64% |
| 2018-12-31 | CN¥2.18 Billion ≈ $319.07 Million |
-2.48% |
| 2017-12-31 | CN¥2.24 Billion ≈ $327.19 Million |
+2.12% |
| 2016-12-31 | CN¥2.19 Billion ≈ $320.39 Million |
+4.77% |
| 2015-12-31 | CN¥2.09 Billion ≈ $305.81 Million |
+8.45% |
| 2014-12-31 | CN¥1.93 Billion ≈ $282.00 Million |
+1.19% |
| 2013-12-31 | CN¥1.90 Billion ≈ $278.69 Million |
-3.26% |
| 2012-12-31 | CN¥1.97 Billion ≈ $288.07 Million |
+0.20% |
| 2011-12-31 | CN¥1.96 Billion ≈ $287.50 Million |
+3.16% |
| 2010-12-31 | CN¥1.90 Billion ≈ $278.71 Million |
+547.64% |
| 2009-12-31 | CN¥294.09 Million ≈ $43.03 Million |
+42.53% |
| 2008-12-31 | CN¥206.34 Million ≈ $30.19 Million |
+45.75% |
| 2007-12-31 | CN¥141.57 Million ≈ $20.72 Million |
-- |
About Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pediatric medicines in China and internationally. It operates through Pharmaceutical Manufacturing and Sales; and Daily Necessities Manufacturing and Sales segments. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal, cough … Read more